Company Overview of Novartis International AG
Novartis International AG offers research, development, manufacture, and marketing of pharmaceuticals. The company manufactures drugs such as clozapine (Clozaril), Jakavi (ruxolitinib), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), and terbinafine (Lamisil). It has strategic alliances with Medicines For Malaria Venture. The company was founded in 1996 and is based in Basel, Switzerland. Novartis International AG operates as a subsidiary of Novartis AG.
Founded in 1996
Key Executives for Novartis International AG
Chief Executive Officer, President, and Division Head of Alcon
Compensation as of Fiscal Year 2016.
Novartis International AG Key Developments
Novartis International AG's Division Alcon Achieves US Approval for Cypass(R) Micro-Stent, Micro Invasive Surgical Device to Treat Glaucoma
Aug 2 16
Novartis International AG's division Alcon announced that it has achieved FDA approval for the CyPass(R) Micro-Stent, a micro invasive glaucoma surgical (MIGS) device to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. CyPass Micro-Stent is the latest addition to Alcon's surgical portfolio providing an additional option to meet the needs of millions of glaucoma patients. The FDA approval is based on the landmark COMPASS Study, the largest MIGS study to date with a two-year follow-up for over 500 mild to moderate glaucoma patients undergoing cataract surgery. The primary effectiveness endpoint was met, with 73% in the CyPass Micro-Stent study group achieving a statistically significant decrease (>= 20%) in intraocular pressure (IOP). The secondary effectiveness endpoint was also met, with 61% of patients in the CyPass study group achieving a target IOP (between 6 and 18 mmHg) at the 24-month postoperative examination without medication, which is a statistically significant difference.
Novartis International AG Expands Partnership with Medicines for Malaria Venture to Develop Next-Generation Antimalarial Treatment
Jun 15 16
Novartis International AG expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment. Processed and transmitted by NASDAQ OMX Corporate Solutions. Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation. KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite's lifecycle. Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies. KAF156 belongs to a novel class of antimalarial molecules and is one of the first antimalarial drug candidates to enter Phase IIb clinical development in more than 20 years. It acts against the two parasites responsible for the majority of malaria deaths (Plasmodium falciparum and Plasmodium vivax) and against both the blood and liver stages of the parasite's lifecycle. Further, it has the potential to provide a more convenient dosing regimen and to address the multidrug resistance that has emerged in five countries of the Great Mekong Sub-region (GMS). KAF156 builds on the heritage of Novartis in antimalarial drug development and the launch in 1999 of Coartem(R), the first fixed-dose Artemisinin-based Combination Therapy (ACT). ACT is the current standard of care in malaria treatment. The Novartis Malaria Initiative is committed to drive research, development and access to novel drugs to eliminate malaria. It is one of the pharmaceutical industry's large access-to-medicine programs. Since 2001, the initiative has delivered more than 750 million treatments without profit, including 300 million dispersible pediatric treatments, developed by Novartis in collaboration with MMV, mostly to the public sector of malaria-endemic countries. Although preventable and treatable, malaria continues to kill a child every two minutes and threatens the lives of many more. It is caused by parasites transmitted to people through the bite of infected mosquitoes. A comprehensive range of interventions is required to eradicate the disease, from bed nets and spraying for prevention to diagnostics and medicines to treat the disease and block its transmission.
Novartis Announces Investment in FortiHFy Clinical Program of Entresto(R) and Heart Failure
May 19 16
Novartis announced the establishment of FortiHFy, the large global clinical program in the heart failure disease area across the pharma industry to date, comprising over 40 active or planned clinical studies designed to generate an array of additional data on symptom reduction, efficacy, quality of life benefits and real world evidence with its novel heart failure medicine Entresto(R) (sacubitril/valsartan), and extend understanding of heart failure. Major trials in the FortiHFy program include: PARAGON-HF examining the efficacy and safety of Entresto in heart failure patients with preserved ejection fraction (compared to valsartan), expected study completion in 2019; PARADISE-MI testing the hypothesis that Entresto can reduce cardiovascular death, heart failure hospitalizations and new onset heart failure in patients at high risk for heart failure after a myocardial infarction, expected study completion in 2020; TRANSITION comparing in-hospital initiation of Entresto to initiation after hospital discharge in heart failure patients with reduced ejection fraction (HFrEF) who have recently been hospitalized for acute decompensation, expected study completion in 2018; PIONEER investigating the effect of in-hospital initiation of Entresto on changes in NT-proBNP (compared to enalapril) in patients with HFrEF following an acute decompensation, expected study completion in 2018. FortiHFy trials that are already active are posted on clinicaltrials.gov and are currently enrolling patients in more than 50 countries worldwide. Entresto is approved in 57 countries to date for the treatment of heart failure with reduced ejection fraction (HFrEF), based on data from the PARADIGM-HF study which reported results in 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions